Search the Newsreel

Gladstone Land to discuss farms and leases in Aug. 12 webcast

Gladstone Land Corporation (NASDAQ:LAND) will host its Q2 2026 earnings call and webcast on August 12, 2026, at 8:30 a.m. ET. The company, a real estate investment trust specializing in farm properties, will discuss its financial results for the quarter ended June 30, 2026. …

Gladstone Land Corporation Earnings Call and Webcast Information

Gladstone Land Corporation (Nasdaq:LAND) has announced the details for its Second Quarter Ended June 30, 2026, earnings call and webcast. The event is scheduled for Wednesday, August 12, 2026, at 8:30 a.m. ET, and will be accessible via webcast and phone. A replay of …

SinoMab Delays Dispatch of Circular on Major Suzhou Asset Disposal

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Agomab Therapeutics NV announced the proposed appointments of Marino Garcia and Dr. Naimish Patel to its Board of Directors, pending shareholder approval at a Special General Meeting on September 11, 2026. Marino Garcia brings extensive experience in biotechnology leadership and financing, currently serving as …

Hemab Therapeutics Holdings (Nasdaq:COAG) - analisi del titolo

Hemab Therapeutics Holdings, Inc. (Nasdaq:COAG) is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders in the US and Denmark. The company's pipeline includes sutacimig (HMB-001) for Glanzmann thrombasthenia and Factor VII deficiency, HMB-002 for Von Willebrand Disease, and the newly …

Genmab (CPSE:GMAB) Lifts 2026 Outlook As Pipeline Progress Keeps Undervalued Narrative Alive

Genmab (CPSE:GMAB) has increased its 2026 revenue outlook after strong Q2 results, regulatory advancements in Europe, and positive Phase III data for key pipeline drugs. Despite a recent share price surge, the stock is considered 16.4% undervalued, with a fair value of DKK2,392.08 compared …

Genmab (CPSE:GMAB) Stock Revenue Strength Meets Profit Pressure

Genmab (CPSE:GMAB) reported strong Q2 2026 revenue of US$1.16 billion, up 24.9% year-over-year, but net income and basic EPS declined. The company's proprietary product sales are growing, particularly EPKINLY and Tivdak, supporting the argument that Genmab is diversifying beyond royalty income. However, profit margins …

AgomAb Therapeutics NV Stock 12‑Month Price Target Cut to $33.16, Implies 146% Upside

AgomAb Therapeutics NV's average 12-month price target has been lowered slightly from $34.2 to $33.16 by six analysts, with forecasts ranging from $27.96 to $36.27 per share. Despite the cut, this updated target still suggests a significant upside of approximately 146% from its recent …

Hemab Therapeutics (NASDAQ: COAG) investors detail 5.1% passive ownership stake

A group of related investment entities, led by Invus Public Equities and Avicenna Life Sci Master Fund, has reported a passive ownership stake in Hemab Therapeutics Holdings, Inc. Raymond Debbane is deemed to beneficially own 5.1% of Hemab Therapeutics' common stock, corresponding to 2,366,235 …

Genmab A/S (GMAB) Aktuelle Aktien-News

Genmab AS earnings beat by $0.15, revenue topped estimates

Genmab AS (NASDAQ: GMAB) reported strong second-quarter results, with EPS of $0.49, exceeding analyst estimates by $0.15. The company also surpassed revenue expectations, bringing in $1.16 billion against a consensus of $1.1 billion. This positive earnings report contributed to significant stock price growth over …

Chemomab Therapeutics Ltd (CMMB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Chemomab Therapeutics Ltd (CMMB) has a "Strong Buy" rating based on 2 analysts, with a target price of USD 26.50, representing a potential upside of 733.33%. The company's previous quarter's EPS was USD -0.24, slightly below the market expectation of USD -0.22, with the …

Guggenheim Boosts Genmab A/S (NASDAQ:GMAB) Price Target to $42.00

Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook

Genmab A/S Stock 12‑Month Price Target Raised to $38.16, Implies 28% Upside

Analysts have increased the average 12-month price target for Genmab A/S (GMAB) stock from $37.7 to $38.16, representing a potential 28% upside from its August 6 closing price. This revised target is based on estimates from 23 analysts, with a consensus "Buy" rating maintained …

Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation. Delcath Systems Inc. (DCTH) Delcath Systems is an interventional oncology company focused on developing therapies for primary and …

FMR LLC reports 7.9% Hemab Therapeutics (COAG) stake on Schedule 13G

FMR LLC has reported a 7.9% beneficial ownership stake in Hemab Therapeutics Holdings Inc (COAG), totaling 3,697,837 shares of common stock, as detailed in a Schedule 13G filing. The investment firm holds sole voting and sole dispositive power over these shares, with Abigail P. …

Why is Genmab stock surging today?

Genmab stock surged 9.2% today after the biotech company reported a strong second-quarter earnings beat and raised its full-year revenue guidance. The positive performance was driven by increased royalty revenues from DARZALEX and stronger net sales of EPKINLY, alongside statistically significant Phase III clinical …

Genmab A/S (NASDAQ:GMAB) Issues Earnings Results, Beats Expectations By $0.12 EPS

Genmab A/S Q2 2026 Earnings Call Transcript

This article first appeared on GuruFocus. Total Revenue Growth: Increased 25% year-over-year in the first half of 2026. Proprietary Portfolio Sales: Totaled DKK396 million, a 37% increase compared to the same period last year. EPKINLY Sales: Grew to DKK312 million in the first half, …

Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

This article first appeared on GuruFocus. Total Revenue Growth: Increased 25% year-over-year in the first half of 2026. Proprietary Portfolio Sales: Totaled DKK396 million, a 37% increase compared to the same period last year. EPKINLY Sales: Grew to DKK312 million in the first half, …

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics NV reported its financial results for the first half of 2026, confirming its outlook for the second half of the year. The company successfully completed its Nasdaq IPO, raising $208 million, which is expected to fund operations into the first half of …

Agomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029

Agomab Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of €30.97 million for the first half of 2026 but secured its financial future by raising $208 million in gross proceeds from a Nasdaq IPO. This capital infusion, bringing their total cash and investments …

Agomab reports €252M cash and expects runway into H1 2029

Agomab (Nasdaq: AGMB) reported a net loss of €31.0 million for the first half of 2026, with €252.0 million in cash and short-term investments as of June 30, 2026. This cash position, bolstered by a $208 million IPO, is expected to fund operations into …

Genmab H1 2026 slides: 25% revenue growth, raised guidance

Genmab reported strong first-half 2026 results, achieving 25% total revenue growth and raising its full-year financial outlook. The company highlighted significant momentum in its proprietary medicines, particularly EPKINLY, which saw 48% year-over-year sales growth. Despite the positive operational update and increased guidance, shares experienced …

Genmab shares jump 8% after upbeat results prompt 2026 outlook raise

Investing.com -- Genmab shares jumped over 8% on Friday, a day after the Danish biotech beat second-quarter expectations and raised its 2026 sales and profit outlook, while confirming a critical bispecific-antibody drug trial readout due in the fourth quarter would be an early look …

Press Release: Genmab Announces Financial Results for the First Half of 2026

Genmab has announced its financial results for the first half of 2026. The company reported significant revenue growth driven by its diverse portfolio of oncology treatments and collaborations. Genmab highlighted strong progress in clinical development programs and reiterated its financial guidance for the full …

Genmab A/S (GMAB) Releases Q2 2026 Earnings: Revenue Up 24.9%, Net Income Falls 9.8%

Genmab A/S (GMAB) reported a 24.9% increase in Q2 2026 revenue, reaching $1.2 billion, while gross profit rose to $1.1 billion. However, net income attributable to common shareholders fell by 9.8% to $303 million, and diluted EPS was $0.49. The company also saw significant …

Genmab Announces Financial Results for the First Half of 2026

Genmab A/S August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival …

Chemomab Therapeutics (Nasdaq:CMMB) - Stock Analysis

Chemomab Therapeutics (Nasdaq:CMMB) is a clinical-stage biotechnology company focused on treatments for fibrotic and inflammatory diseases. The company faces significant risks, including a highly volatile share price, shareholder dilution, and projected earnings decline, with recent news dominated by a proposed reverse merger with Scipher …

Sofinnova group (NASDAQ: COAG) discloses 5.4% Hemab Therapeutics ownership on Schedule 13G

Sofinnova Crossover II SLP, along with Sofinnova Partners SAS and its investment committee members, has reported a beneficial ownership of 2,511,212 shares of Hemab Therapeutics Holdings, Inc. common stock. This constitutes a 5.4% stake in the company, based on 46,705,410 shares outstanding as of …

Heng Tai Consumables Updates Board Roles and Committee Structure

Hemab Therapeutics Holdings Ord Shs (Proposed)

Genmab A/S (GMAB) Earnings Date and Reports 2026

Genmab A/S (GMAB) raises 2026 outlook on DARZALEX and EPKINLY growth

We Think AgomAb Therapeutics (NASDAQ:AGMB) Can Afford To Drive Business Growth

AgomAb Therapeutics (NASDAQ:AGMB), despite being unprofitable, is considered to have a manageable cash burn. With €117m in cash reserves and a burn rate of €52m per year, the company has a cash runway of about 2.3 years. While its cash burn increased by 8.9% …